Levodopa-Induced Dyskinesia in Parkinson's Disease

 
 
Springer (Verlag)
  • erschienen am 8. Oktober 2014
  • |
  • XII, 368 Seiten
 
E-Book | PDF mit Wasserzeichen-DRM | Systemvoraussetzungen
978-1-4471-6503-3 (ISBN)
 

This book aims to provide a single reference source on levodopa-induced dyskinesias (LID) from 'bench to bedside'.

Initial chapters review the clinical features and phenomenology of LID with video examples; epidemiology and genetic risk factors for LID are covered as a background to understanding risk factors for developing LID. The following chapters cover the latest preclinical studies aiming to understand the pathophysiology of LID at the cellular, neurochemical, neurophysiological and circuitry level with detailed discussion of mechanisms and future directions to take the field forward; clinical studies from phase II to phase IV; on going RCTs in LID and evidence-based medicine reviews of treatment options.

Levodopa-Induced Dyskinesia in Parkinson's Disease is aimed at an international audience of movement disorder neurologists; neuroscientists; trainees and graduate and post-graduate students.

2014
  • Englisch
  • London
  • |
  • Großbritannien
  • 11
  • |
  • 1 s/w Abbildung, 26 s/w Tabellen, 11 farbige Abbildungen
  • |
  • 1 schwarz-weiße und 11 farbige Abbildungen, 26 schwarz-weiße Tabellen, Bibliographie
  • 6,11 MB
978-1-4471-6503-3 (9781447165033)
10.1007/978-1-4471-6503-3
weitere Ausgaben werden ermittelt

Dr Susan Fox is Associate Professor of Neurology at Toronto Western Hospital, University Health Network and University of Toronto, Canada. She has many years' experience in preclinical models of Parkinson's disease and translational studies of novel pharmacological therapies for Parkinson's disease and dyskinesia. She has expertise in the design and running of phase II and III clinical studies in movement disorders. She has received funding from NIH, CIHR, Parkinson Society Canada and Michael J Fox Foundation for research into PD. She has published over 120 peer reviewed papers, reviews and book chapters in the field and is a regular speaker at national and international conferences. Dr Fox is an active member of the International Parkinson and Movement Disorder Society (MDS). She is current co-editor of the MDS website and chair of the MDS evidence based medicine committee on reviews of treatments for movement disorders.

Jonathan Brotchie, PhD, is Senior Scientist at the Toronto Western Hospital, University Health Network (UHN). At UHN, he leads a research programme focused on the discovery and validation of novel therapeutic targets for Parkinson's disease and the development of therapeutics based upon those targets. The particular expertise of his group and collaborators at UHN lies in transitioning development programmes from pre-clinical efficacy to Phase II proof-of-concept. Dr Brotchie is also Founder and a Director of Atuka Ltd, a CRO specialising in the provision of support for developing therapies for neurodegenerative disorders.

Phenomenology of Levodopa-Induced Dyskinesia.- Dyskinesia Rating Scales in Parkinson's Disease.- Epidemiology of Levodopa-Induced Dyskinesia.- Risk Factors for Levodopa-Induced Dyskinesia.- Pharmacological Treatment Options for Levodopa-Induced Dyskinesia.- Surgical Options for Levodopa-Induced Dyskinesia in Parkinson's Disease.- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia.- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia.- Pharmacological Properties of Levodopa.- Dopamine Receptors and LID.- The Serotonergic System In Levodopa-Induced Dyskinesia.- The Opioid System in Levodopa-Induced Dyskinesia.- Glutamate Receptors and Levodopa-Induced Dyskinesia.- Cannabinoids and Levodopa-Induced Dyskinesia.- The Role of the Noradrenergic System and its Receptors In Levodopa-Induced Dyskinesia.- Involvement of the Cholinergic System in Levodopa-Induced Dyskinesia.- New Clinical Trials for Levodopa-Induced Dyskinesia.- Preclinical Models of Levodopa-Induced Dyskinesia.- Final Thoughts: Summary and Future Therapeutic Strategies in LID.

Dateiformat: PDF
Kopierschutz: Wasserzeichen-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Verwenden Sie zum Lesen die kostenlose Software Adobe Reader, Adobe Digital Editions oder einen anderen PDF-Viewer Ihrer Wahl (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie die kostenlose App Adobe Digital Editions oder eine andere Lese-App für E-Books (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nur bedingt: Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Wasserzeichen-DRM wird hier ein "weicher" Kopierschutz verwendet. Daher ist technisch zwar alles möglich - sogar eine unzulässige Weitergabe. Aber an sichtbaren und unsichtbaren Stellen wird der Käufer des E-Books als Wasserzeichen hinterlegt, sodass im Falle eines Missbrauchs die Spur zurückverfolgt werden kann.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

117,69 €
inkl. 7% MwSt.
Download / Einzel-Lizenz
PDF mit Wasserzeichen-DRM
siehe Systemvoraussetzungen
E-Book bestellen